Chronic Kidney Disease Clinical Trial
Official title:
Evaluation of Synergy of Combining Hydroxyurea With Recombinant Human Erythropoietin Glycoform Alpha (Rhu Erythropoietin-alpha) on Fetal Hemoglobin Synthesis in Patients With Sickle Cell Anemia
Verified date | January 27, 2016 |
Source | National Institutes of Health Clinical Center (CC) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will examine the use of hydroxyurea and erythropoietin for treating sickle cell
disease in patients who also have kidney disease or pulmonary hypertension (high blood
pressure in the lungs). Hydroxyurea increases production of fetal hemoglobin in the red blood
cells of patients with sickle cell disease, reducing the amount of sickle cells that cause
pain and other complications requiring hospitalizations. However, hydroxyurea treatment has
limitations: patients with sickle cell disease who have developed kidney disease may not be
able to get the full benefit of the medicine, and hydroxyurea alone may not be able to treat
life-threatening complications such as pulmonary hypertension or stroke. This study will
determine which of two dosing schedules of hydroxyurea and erythropoietin is more effective
for treating patients with sickle cell disease who also have kidney disease or pulmonary
hypertension, and will examine whether the two drugs can lower blood pressure in the lungs.
Patients 18 years of age and older with sickle cell anemia and kidney disease or pulmonary
hypertension, or both, may be eligible for this study. Candidates are screened with a medical
history, physical examination, blood tests, a 6-minute walk test (test to see how far the
subject can walk in 6 minutes), and echocardiogram (ultrasound of the heart to measure blood
pressure in the lungs).
Participants undergo the following tests and procedures:
Stabilization Phase: Patients take 2 hydroxyurea tablets a day until their fetal hemoglobin
levels stabilize, usually over 2 to 4 months. They have blood tests every 2 weeks to monitor
hemoglobin and fetal hemoglobin levels. At some time during this period, they undergo a test
to measure kidney function, in which they are injected with an iodine-containing dye and wear
a small pump for 1 day that injects a small amount of dye under the skin over 24 hours. They
come to the clinic for 2 or 3 blood tests collected over 4 hours.
Sequence I (Standard): When the fetal hemoglobin levels have been stable for 2 months,
patients have a repeat echocardiogram and 6-minute walk test. Erythropoietin is then added to
the hydroxyurea regimen. It is given 3 days a week, as an injection under the skin, along
with iron supplements. Patients have blood tests and blood pressure measurements every week
or every other week. Patients with pulmonary hypertension have another echocardiogram and
6-minute walk test once the hemoglobin level is stable.
Sequence II (Cycled): When hemoglobin levels have stabilized with hydroxyurea once a day and
erythropoietin 3 times a week, the hydroxyurea is adjusted so that the amount taken in 7 days
is "cycled" over 4 days, and the erythropoietin is cycled over 3 days, with the dose
increased twice, every 3 to 4 weeks. Blood pressure and hemoglobin are monitored once or
twice a month. Patients with pulmonary hypertension have another echocardiogram and 6-minute
walk test once the hemoglobin level is stable.
Patients who develop complications while taking the drugs have their treatment regimens
adjusted as needed.
Status | Completed |
Enrollment | 7 |
Est. completion date | August 31, 2009 |
Est. primary completion date | August 31, 2009 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
- INCLUSION CRITERIA: Patients with homozygous SCD or other sickling disorders (e.g., B(0) Thalassemia/Sickle) who are 18 years of age or greater will be eligible for treatment. Patients currently being followed on an NIH study or at Howard University on stable doses of hydroxyurea are also eligible. A total of 60 patients will be recruited to the study, with the recognition from our earlier studies of a failure-to-complete rate approaching 50%. Patients must have documented hemoglobin S-only or S-beta(0)-thalassemia. Patients must have relatively well preserved hepatic function (less than 3 X upper limits of normal ALT). Patients must be able to provide informed consent. Patients must have: -an eGFR of 15 to 60 ml/min per 1.73 m(2) BSA, or an eGFR of 61 - 90 ml/min per 1.73 m(2) BSA and greater than 16.9 mg of albumin/g creatinine (greater than 0.017 ratio g/g), and/or a trans-thoracic echocardiographic measurements of pulmonary artery pressure (PAP), as estimated by tricuspid regurgitant velocity, of greater than 2.5 m sec(-1) monthly at baseline times two. EXCLUSION CRITERIA: Patients who are doubly heterozygous for hemoglobin-S and fully or partially expressed hemoglobin-A or any other non-S beta-type globin chain, or hemoglobin A-only (non-sickle cell). Patients who are on a chronic transfusion program, defined as regular transfusions every 2-8 weeks. Patients who are pregnant or breast-feeding. Patients who have a history of a documented cerebrovascular accident or venous thrombosis within one year of study entry. Patients with active proliferative retinopathy within 1 year of study entry Patients with eGFR less than or equal to 14 ml/min per 1.73 M(2) BSA. Patients with a total Hgb at entry that is 10.5 g/dl or greater Patients with a known allergy to Albumin or cell-derived products Patients with uncontrolled hypertension, defined as a systolic blood pressure greater than 170 mmHg and diastolic blood pressure greater than 110 mm Hg that is sustained and unresponsive over 1 week to conventional anti-hypertensive therapy . |
Country | Name | City | State |
---|---|---|---|
United States | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Heart, Lung, and Blood Institute (NHLBI) |
United States,
McKerrell TD, Cohen HW, Billett HH. The older sickle cell patient. Am J Hematol. 2004 Jun;76(2):101-6. — View Citation
Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994 Jun 9;330(23):1639-44. — View Citation
Platt OS, Thorington BD, Brambilla DJ, Milner PF, Rosse WF, Vichinsky E, Kinney TR. Pain in sickle cell disease. Rates and risk factors. N Engl J Med. 1991 Jul 4;325(1):11-6. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | An increase in fetal hemoglobin, as measured by high performance liquid chromatograph, from hydroxyurea alone/stabilized baseline to concurrent Erythropoietin in standard therapy/sequence l. | |||
Secondary | (All measured, at a minimum, at study entry, at change of dose, and with stabilization at the conclusion of each Erythropoietin sequence, standard or cycled). |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Terminated |
NCT04043026 -
The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function
|
||
Completed |
NCT05318014 -
Low-protein Formula Supplements in Chronic Kidney Disease
|
N/A | |
Active, not recruiting |
NCT06071065 -
Clinical Pharmacist Intervention on Medication Adherence and Clinical Outcomes in Chronic Kidney Disease Patients
|
N/A | |
Completed |
NCT02878317 -
Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.
|
||
Not yet recruiting |
NCT06039254 -
Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function
|
Phase 1 | |
Recruiting |
NCT03160326 -
The QUALITY Vets Project: Muscle Quality and Kidney Disease
|
||
Completed |
NCT02756520 -
Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)
|
||
Completed |
NCT02875886 -
DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease
|
Phase 4 | |
Completed |
NCT02896309 -
The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity
|
N/A | |
Completed |
NCT02836574 -
A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease
|
Phase 2 | |
Withdrawn |
NCT02885545 -
The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial
|
Phase 4 | |
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Active, not recruiting |
NCT02483039 -
Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization
|
N/A | |
Completed |
NCT02369549 -
Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease
|
Phase 3 | |
Terminated |
NCT02543177 -
Optimised Procedure in Patients With NSTEMI and CKD
|
N/A | |
Completed |
NCT02992548 -
Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease
|
Phase 4 | |
Recruiting |
NCT02205944 -
Impact of Presurgical Exercise on Hemodialysis Fistula Outcomes
|
N/A | |
Active, not recruiting |
NCT02231138 -
Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease
|
Phase 4 |